Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis.
The prognostic value of different pretreatment laboratory and clinical findings at diagnosis was assessed in a series of 141 patients with generalized non-Hodgkin's lymphoma. Univariate and multivariate survival analysis (Cox's regression model) was performed, using serum analysis of deoxythymidine kinase (S-TK), beta 2-microglobulin, lactic dehydrogenase, alpha 1-acid glycoprotein = orosomucoid (S-alpha 1 AGP), haptoglobin and ferritin. In addition, Hb and the erythrocyte sedimentation rate (ESR) were measured. The clinical variables were age, presence or absence of B-symptoms, histopathology ('low-grade'; 'intermediate grade' and 'high-grade' malignancy) and bone marrow involvement. Of the 8 biochemical markers, all except Hb and the ESR showed a significant relationship to survival. Among the clinical variables, this finding was made for B-symptoms and histopathology. Using a multivariate analysis on all variables, S-TK was found to be the best factor for predicting duration of survival. The only significant additional information was provided by S-alpha 1 AGP. When only the clinical variables were taken into account, it was found that histopathology added significant information to that yielded by B-symptoms in the prediction of the survival time. When the biochemical variables were added to this model, only S-TK was of significant additional prognostic value.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001799:Blood Sedimentation; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005293:Ferritins / Q000097:blood; D006242:Haptoglobins / Q000097:blood; D006454:Hemoglobins; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008223:Lymphoma / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D009961:Orosomucoid / Q000097:blood; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D013937:Thymidine Kinase / Q000097:blood; D014750:Vincristine / Q000008:administration & dosage; D001613:beta 2-Microglobulin / Q000097:blood
D006242:Haptoglobins; D006454:Hemoglobins; D009961:Orosomucoid; D001613:beta 2-Microglobulin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005293:Ferritins; D007770:L-Lactate Dehydrogenase; D013937:Thymidine Kinase; D011241:Prednisone; D008727:Methotrexate